The 2026 domestic cyclosporiasis season is, by CDC’s own case counts, the largest since the agency began national surveillance of the parasite. But the story most coverage is telling — recalled lettuce, symptom checklists, “is it safe to eat salad” — is not the one clinical and public health laboratories need. The harder problem is diagnostic: Cyclospora cayetanensis is a parasite that routine stool testing is structurally likely to miss, and this outbreak’s scale is as much a story about detection catching up to transmission as it is about a contaminated crop.
The numbers, and why every one of them needs a date attached
Three separate CDC data streams are in play for this outbreak, and they answer different questions. Conflating them — which a lot of secondary coverage has done — overstates or understates the picture depending on which number gets picked up.
- National domestic surveillance (broadest denominator): CDC’s cyclosporiasis surveillance page reports 10,468 laboratory-confirmed domestically acquired cases since May 1, 2026, with several thousand additional cases still under investigation, as of its most recent update. This is the full-season national count, not specific to any single food source.
- The iceberg lettuce / Taylor Farms de Mexico outbreak specifically: the subset of cases CDC and FDA have linked by epidemiologic and traceback evidence to a single recalled product. CDC’s investigation page for this cluster has reported roughly 1,900+ confirmed cases across at least 15 states, with several hundred hospitalizations and two deaths reported in Michigan, as case counts continued to rise through late July into August.
- FDA traceback footprint: the geographic distribution footprint of the recalled Taylor Farms de Mexico iceberg lettuce, which FDA has been expanding as distribution records come in — reported growing from an initial 9 states to 15 states by early August 2026.
As of CDC’s most recent public update (accessed 2026-08-07), the count of laboratory-confirmed domestic cases stood at 10,468 for the season, with additional cases still under investigation. That number has moved by roughly an order of magnitude across a few weeks of reporting and will move again before this outbreak is declared over — CDC issued its first Health Alert Network notice on this outbreak (HAN00531) on July 14, 2026, and has published updates on a rolling weekly basis since. Any figure quoted below should be read as a snapshot tied to the date given, not a final total. See CDC’s cyclosporiasis surveillance page and the outbreak-specific investigation update for the current figures at the time you’re reading this.
Why this parasite gets missed in the lab
Cyclospora cayetanensis is a coccidian parasite that causes prolonged, often relapsing watery diarrhea, and it is a well-documented diagnostic blind spot in general clinical microbiology — not because the organism is exotic, but because standard specimen workflows aren’t built to catch it. Three structural reasons drive this, all discussed in CDC’s clinical and laboratory guidance:
- Routine ova-and-parasite (O&P) exams can miss it. Cyclospora oocysts are small (8–10 micrometers), and a standard O&P wet mount or trichrome-stained smear — tuned for the helminth eggs and larger protozoa most labs see routinely — does not reliably resolve them. A lab that runs only a generic O&P and reports it negative has not ruled Cyclospora out; it has simply not looked for it with a method capable of finding it.
- Not every GI PCR panel includes a Cyclospora target. Multiplex gastrointestinal PCR panels have become the default first-line stool test in many hospital labs, and clinicians often assume a negative panel excludes parasitic causes. But several widely used commercial panels do not include a Cyclospora-specific target at all, which means a “comprehensive” negative panel can still be a false reassurance for this organism specifically.
- Intermittent, low-level oocyst shedding. Even symptomatic patients may not shed enough oocysts in a single stool specimen to be detected. CDC guidance notes that patients may need to submit multiple specimens collected on different days before a diagnosis is confirmed, which has direct implications for how a lab and ordering clinician should handle an initial negative result in a patient with a compatible travel or exposure history.
What actually detects it: staining and molecular methods
Per CDC’s DPDx laboratory identification guidance and its clinical overview for cyclosporiasis, confirmed diagnosis relies on methods specifically chosen (or run in addition to routine O&P) to visualize or amplify Cyclospora oocysts:
- Modified acid-fast (MAF) or modified “hot” safranin staining. These acid-fast-family stains render the oocyst wall visible in a way that standard trichrome staining does not. CDC guidance notes MAF slides have historically carried a higher false-negative rate relative to other detection methods, which is part of why a single negative acid-fast smear is not by itself considered sufficient to rule the parasite out in a patient with a compatible clinical picture.
- UV fluorescence microscopy (autofluorescence). Cyclospora oocysts are autofluorescent under ultraviolet light, appearing blue when unstained stool concentrate is examined under a UV fluorescence microscope. CDC guidance describes UV fluorescence as performing comparably to modified acid-fast staining, with reported higher agreement between readers — a meaningful consideration for labs deciding which method to run as their primary screen versus confirmatory step.
- Molecular (PCR) testing. PCR assays that specifically target Cyclospora — whether a dedicated singleplex assay or a multiplex GI panel that explicitly includes a Cyclospora target — offer higher sensitivity than microscopy, particularly useful given the low, intermittent oocyst shedding described above. (For background on how PCR reactions are actually assembled and run, see CASRAI’s PCR protocol basics guide.) The caveat above bears repeating here: a negative result from a panel that does not carry a Cyclospora target proves nothing about Cyclospora specifically.
The practical guidance CDC and state health departments (several, including Texas DSHS, issued their own advisories during this outbreak) have converged on for clinicians and labs during an active outbreak is the same: do not rely on a routine O&P alone. Order specimen testing with a method — modified acid-fast stain, UV fluorescence, or a PCR panel confirmed to include a Cyclospora target — that is actually capable of detecting the organism, and consider repeat specimens on separate days if clinical suspicion remains high after an initial negative.
Specimen handling and reporting considerations
A few specimen-handling points matter specifically for Cyclospora, distinct from general stool-culture practice:
- Unpreserved or appropriately preserved stool (per the receiving lab’s protocol — formalin or SAF-type fixatives are commonly used for O&P-adjacent workflows) should be collected with the specific test method in mind, since not all preservation methods are compatible with every detection method a lab might subsequently want to run. Clinical laboratories performing this testing operate under CLIA certification requirements appropriate to the complexity of the methods used, and specimen provenance should be documented consistently with the lab’s chain-of-custody procedures, particularly where a specimen may later be needed for outbreak-related public health follow-up.
- Because a single specimen can be falsely negative, clinicians managing a patient with a compatible exposure history and persistent symptoms should be prepared to request repeat testing on specimens collected on different days rather than treating one negative result as definitive.
- Cyclosporiasis is a nationally notifiable condition. Confirmed and probable cases identified by clinical or public health laboratories should be reported to state or local health departments promptly, both to support the patient’s care and because case-level reporting is what feeds the national surveillance and traceback picture described above — the same pipeline that let CDC and FDA connect this season’s case cluster to a specific lettuce supplier.
The source: what traceback established
FDA and CDC traceback and epidemiologic investigation — interviews with sick people about what they ate, combined with distribution-record analysis — identified iceberg lettuce from Taylor Farms de Mexico, sourced from central Mexico, as the vehicle for the largest linked cluster in this outbreak. Taylor Farms issued a recall of iceberg lettuce from that supply source in mid-July 2026. FDA’s traceback investigation, which maps how a contaminated product moved through distribution to reach the states where illnesses were reported, was reported to have expanded from an initial 9 states to 15 states as of 2026-08-06 — a reminder that the geographic footprint of a foodborne outbreak investigation is itself provisional and typically grows as records are obtained, not a fixed fact established on day one.
For laboratories and clinicians, the traceback story matters less than the surveillance takeaway it supports: cyclosporiasis is not solely a returning-traveler diagnosis anymore in the way older clinical teaching sometimes still frames it. Domestically acquired, foodborne cyclosporiasis in patients with no relevant travel history has been a growing pattern across multiple U.S. seasons, and 2026 is the clearest illustration of it yet. A negative travel history should not lower clinical or laboratory suspicion during an active domestic outbreak.
Key takeaways for clinical and public health laboratories
- A negative routine O&P does not rule out Cyclospora. Order a method built to detect it — modified acid-fast/safranin stain, UV autofluorescence microscopy, or a PCR assay confirmed to carry a Cyclospora target.
- Confirm whether your lab’s (or your reference lab’s) multiplex GI PCR panel actually includes a Cyclospora target before treating a negative panel result as excluding the parasite.
- Low-level, intermittent oocyst shedding means a single negative specimen in a symptomatic, epidemiologically compatible patient may warrant repeat testing on a separately collected specimen rather than closing the workup.
- Report confirmed and probable cases promptly — cyclosporiasis is nationally notifiable, and timely reporting is the mechanism that connects individual lab results into the outbreak surveillance and traceback picture.
- Treat every case count in this outbreak, including the ones in this article, as time-stamped snapshots. Check CDC’s surveillance and outbreak investigation pages directly for the current figures.
